Concurrent chemotherapy, proton therapy improves survival in patients with advanced lung cancer
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from Â鶹ӳ» MD Anderson Cancer Center.
The research, published in JAMA Oncology, reported an overall survival (OS) of 26.5 months. In contrast, the historical OS rate with standard...
Genetically enhanced, cord-blood derived immune cells strike B-cell cancers
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down...
Tumor-targeting drug shows potential for treating bone cancer patients
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by Â鶹ӳ» MD Anderson Cancer Center...
Recommendation for the further treatment of Chinese Nobel Prize Laureate Liu Xiaobo
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, Â鶹ӳ» MD Anderson Cancer Center, and Dr. Markus B¨¹chler, Chairman, Department of Surgery, University of Heidelberg
On Saturday, July 8, Dr. Joseph M. Herman of Â鶹ӳ» MD Anderson Cancer Center and Dr. Markus W B¨¹chler of University of Heidelberg met with the medical team at the No. 1 Hospital...